Kneat.com, Inc.

TSX:KSI.TO

Medical - Healthcare Information Services

Healthcare
$6.50 -0.16%

-$0.01 today

Market cap
$624.86M
Beta
1.37
P/E (TTM)
-73.0
EPS (TTM)
-$0.09
52W Low $3.23High $6.44

Volume 0.10M

Average 0.31M

KSI.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Kneat.com, Inc.TSX: KSI.TO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of CA$3.19M fell 32.2% year over year, behind the -25.6% change in trailing-twelve-month research & development. Sequentially, it rose 61.6% from the prior quarter. Over 3 fiscal years it compounded at -7.0% a year.

Context

  • Research & development amounted to 14.0% of revenue in FY2025, down 21.3 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -32.2% toward the trailing-twelve-month pace of -25.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$3.19M+61.6% QoQ
Last fiscal yearDec 2025
CA$8.84M-48.8% YoY
LTMMar 2026
CA$13.33M-25.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.2%——
1 year-48.8%——
3-year CAGR-7.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
8.84M CAD
Year-over-year change
-48.8%
4-year CAGR
+1.5%

Research & Development vs competitors

How KSI.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -25.6% is the 4th highest of 6, against a peer median of +31.9%.
  • Research & development amounts to 20.0% of revenue for KSI.TO, versus a peer median of 4.1%.
KSI.TO Competitors
Research & Development for KSI.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$33.61M CAD+45.4%+25.2%6.6%
VHI.TOVitalhub Corp.LTM Mar 2026CA$32.77M CAD+92.4%+40.5%27.5%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$13.33M CAD-25.6%-7.0%20.0%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$4.85M CAD+31.9%-15.1%1.5%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$1.84M CAD-59.9%—66.7%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-39.8%0.0%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding KSI.TO) —+31.9%+5.1%4.1%

Competitors are the stored peer set for KSI.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15.5M23.75M34.22M48.94M63.26M
Cost of Revenue6.18M9.09M11.09M12.18M28.56M
Gross Profit9.32M14.65M23.13M36.76M34.7M
Gross Margin60.1%61.7%67.6%75.1%54.9%
Research & Development8.33M10.99M15.76M17.27M8.84M
Selling, General & Admin7.35M13.44M20.98M25.44M34.31M
Operating Expenses15.67M24.43M36.74M42.71M43.15M
Depreciation & Amortization4.44M5.7M7.61M10.13M13.99M
EBITDA(5.11M)(3.2M)(5.37M)6.27M5.54M
EBITDA Margin-33.0%-13.5%-15.7%12.8%8.8%
Operating Income(6.35M)(9.77M)(13.53M)(5.95M)(8.45M)
Operating Margin-41.0%-41.2%-39.5%-12.2%-13.4%
Interest Income6.45K2.75K6.64K678.39K516.74K
Interest Expense284.95K228.59K1.08M3.67M3.43M
Other Income / Expenses(3.48M)642.86K(529.44K)(1.59M)6.26M
Income Before Tax(9.84M)(9.13M)(14.06M)(7.53M)(2.19M)
Pre-Tax Margin-63.5%-38.5%-41.1%-15.4%-3.5%
Income Tax Expense20.91K16.61K55.89K192.6K158.86K
Net Income(9.86M)(9.15M)(14.12M)(7.73M)(2.35M)
Net Margin-63.6%-38.5%-41.3%-15.8%-3.7%
EPS (Basic)(0.13)(0.12)(0.18)(0.09)(0.02)
EPS (Diluted)(0.13)(0.12)(0.18)(0.09)(0.02)
Weighted Avg Shares74.11M77.44M77.83M86.55M94.91M
Weighted Avg Shares (Diluted)74.11M77.44M77.83M86.55M94.91M

Kneat.com, Inc.

TSX:KSI.TO

Intrinsic Alpha fair value

Locked

Current Price

$6.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.